Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Pancreatic Cancer Oncologists in the U.S.(?)

Council Members in this Study Group: 63

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

Ben Ebrahimi, MD
Consultant
Medical Consulting Firm of Dr. Ben Ebrahimi

Ben Ebrahimi, MD, is Director of Clinical Trials at Wilshire Oncology Medical Group. Dr. Ebrahimi oversees clinical trials in various tumor types and treats a variety of cancer patients including lung, breast, colorectal, and lymphomas. These clinical trials include biological agents as well as targeted...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Sujith Kalmadi
Staff Physician
Ironwood Cancer & Research Center

Sujith Kalmadi, MD, is a Staff Physician at the Ironwood Cancer and Research Center in Phoenix, Arizona. Dr. Kalmadi has previously worked as a Clinical Assistant Professor at Baylor school of Medicine in Houston, Texas, and at the Lerner School of Medicine at the Cleveland Clinic, Ohio. He has interest...

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD
Medical Director of Hematology
Big Sky Oncology

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...

Federica Bertolini, MD
Medical Oncologist and Researcher
Università di Modena e Reggio Emilia

Federica Bertolini, MD, is a Medical Oncologist and Researcher in the Division of GI Medical Oncology at Policlinico di Modena at the University Of Modena and Reggio Emilia. Dr. Bertolini has expertise in treatment of all gastro-intestinal tumors such as colorectal cancer or pancreatic cancer and is...

Haitham Al-Okk, MD, Assistant Clinical Professor - Hematology-Oncology, Mahr Cancer CenterHaitham Al-Okk, MD
Assistant Clinical Professor - Hematology-Oncology
Mahr Cancer Center

Haitham Al-Okk, MD, is an Assistant Clinical Professor of Hematology-Oncology at Mahr Cancer Center, affiliated with the University of Louisville Brown Cancer Center. Dr. Al-Okk is board certified in Internal Medicine and Medical Oncology, and fellowship trained in Hematology-Oncology. He specializes...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
UK the model for US healthcare? | 08-14-2008
Analysis of: UK Says Kidney Cancer Drugs Are Too Pricey | www.pharmalot.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

In this election year some have encouraged adoption of socialized medical services UK healthcare is an example of what some in this country have said we need to model our future healthcare system The recent use of biologics such as the TKIs have resulted in options for...

EGFR and Non Small Cell Lung Cancer ( NSCLCa) | 07-24-2008
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Recent BMS subanalysis indicate despite negative trial, EGFR indicates favorable outcome with platinum therapy EGFR will become target for frontline NSCLCa

Cancer Care Is getting out of reach | 07-10-2008
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

The cost of medical care is increasing at an alarming rate The amount of money to support a physician's practice is going down at the same alarming rate especially in oncology

Should we use cetuximab in all NSCLC patients? | 06-02-2008
Author: GLG Expert Contributor

  The FLEX trial, a randomized phase 3 study comparing cisplatin-vinorelbine versus the same regimen plus cetuximab, recently showed that the addition of the monoclonal antibody to chemotherapy significantly prolong survival in chemonaive NSCLC. Several aspects could limit the wide use...

Erbitux and Lung cancer | 05-23-2008
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Consultancy, Healthcare-Focused
  • Other Freestanding Healthcare Facility

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Director
  • Partner
  • Physician - Department Chair
  • Research Scientist
  • President
  • Consultant
  • Owner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics